Almirall acquires rights to Alzheimer's product in Spain

5 September 2023

Shares of Spanish dermatology-focused drugmaker Almirall (BME: ALM) rallied yesterday, after the company revealed in a brief stock exchange filing that it is looking to expand its therapeutic range.

In the fling, Almirall announced the execution of acquisition rights for an Alzheimer’s product in Spain. This agreement grants Almirall exclusive rights.

The product is a transdermal patch with rivastigmine to treat Alzheimer’s disease, increasing the level of neurotransmitter acetylcholine helping to reduce the symptoms of Alzheimer’s. It brings Almirall the opportunity to reinforce its neurology business unit in Spain, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK